Kirwin Patrick D. 4

What Happened

• Patrick D. Kirwin, a director of ProMIS Neurosciences (PMN), acquired 3,050 common shares on February 3, 2026 at $12.13 per share for a reported cash outlay of $36,997. The filing also shows he received 3,050 common share purchase warrants (derivative securities) related to the same transaction.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (appears timely).
• Share purchase: 3,050 common shares at $12.13 each (total $36,997).
• Derivative acquisition: 3,050 common share purchase warrants listed as acquired; the Form 4 shows N/A for the warrant price/value line, though the footnote states the purchase price was $12.13 per Common Share and Common Share Warrant.
• Shares owned after the transaction: not specified in the filing.
• Reverse split: filing reflects a 1-for-25 reverse split of common shares that took effect November 28, 2025 (affects historical share counts).
• Warrant terms: warrants expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days after a public announcement or Form 8-K reporting topline single-ascending-dose PMN310 cohort data.

Context

• This is a cash acquisition (reported as an "A" award/acquisition) rather than a sale; purchases by insiders can be seen as a stronger signal than routine sales but do not by themselves prove future performance. The warrants provide the right to purchase additional shares under the terms above; the Form 4 does not detail an exercise price beyond the filing footnote and does not indicate immediate sale of any acquired securities.